https://doi.org/10.18502/ijrm.v22i3.16167
statistics
- 135 Abstract Views
- 58 PDF Views
- 0 HTML Views
authors
-
Shaimerdenova Gulbanu Ganikyzy
Shaimerdenova Gulbanu Ganikyzy
South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
-
Gulzhan Narkenovna Abuova
Gulzhan Narkenovna Abuova
South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
-
Saltanat Kulbayeva Nalibekkyzy
Saltanat Kulbayeva Nalibekkyzy
South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
Published Date
- May 12, 2024
Features of the course of severe and critical COVID-19 in pregnant women: A prospective cross-sectional study
Abstract
Background: At the beginning of the Coronavirus disease 2019 (COVID-19) pandemic, studies showed that the risk of severe disease was higher in pregnant women.
Objective: This study investigates the characteristics of severe and critical types of COVID-19 coronavirus infection in pregnant women.
Materials and Methods: This prospective cross-sectional study compared the medical records of 120 pregnant women with severe and very severe COVID-19 treated at the Infectious Disease Center, Shymkent, Kazakhstan from December 2021 to May 2022. Factors such as time of hospital admission, hospitalization period, maternal comorbidities, age, pregnancy and postpartum complications, pregnancy outcomes, and treatment type were analyzed.
Results: 87 (72.5%) pregnant women with severe and 33 (27.5%) with critical type of COVID-19 were included. The following data were obtained when comparing the pregnancy parity of the subjects, depending on the gestational age: in 1–12 wk, the indicator was 3.75 ± 0.95; in 13–27 wk3.00 (Q1-Q3: 2.00–4.00), in 28–40 wk 3.00 (Q1-Q3: 2.00–4.00). Severe COVID-19 coronavirus infection occurs in women with more than a third pregnancy (Me 3.00 [Q1-Q3: 2.00–4.00]).
Conclusion: There is a risk of disease progression to severe and critical COVID-19 in pregnant women older than 33 yr of age and at 28–40 wk gestation. Early referral to a doctor in hospital, timely hospitalization, and initiated treatment reduces the risk of aggravation of the patient’s condition and development of formidable complications.
Key words: COVID-19, Pregnancy, Infection.
References
[2] World Health Organization. Novel coronavirus (2019- nCoV). Situation report 22. Available at: https://www.who. int/docs/default-source/coronaviruse/situation-reports/ 20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. 11 February 2020.
[3] Shchelkanov MY, Popova AY, Dedkov VG, Akimkin VG, Maleev VV. [The history of investigation and modern classification of coronaviruses (Nidovirales: Coronaviridae)]. Russian J Infect Immun 2020; 10: 221– 246. (In Russian)
[4] Estimated cumulative excess deaths per 100,000 people during COVID-19. Available at: https://ourworldindata.org/ explorers/coronavirus-data-explorer07/16/2022.
[5] Data of the committee for sanitary and epidemiological control of the city of Shymkent, 2022. Available at: https://www.gov.kz/memleket/entities/ departament-kkbtu-shymkent?lang=ru07/16/2022.
[6] Elshafeey F, Magdi R, Hindi N, Elshebiny M, Farrag N, Mahdy S, et al. A systematic scoping review of COVID- 19 during pregnancy and childbirth. Int J Gynecol Obstet 2020; 150: 47–52.
[7] Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, et al. Perinatal transmission of 2019 coronavirus Disease: Associated severe acute respiratory syndrome coronavirus 2: Should we worry? Clin Infect Dis 2021; 72: 862–864.
[8] Joseph NT, Collier AY. COVID-19 therapeutics and considerations for pregnancy. Obstet Gynecol Clin North Am 2023; 50: 163–182.
[9] Shaimerdenova GG, Abuova GN, Saltanat S, Baimbetova S, Aidana A. Remdesevir antiviral therapy in pregnant women with COVID-19. Arch Clin Infect Dis 2023; 18: e132803.
[10] Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, Da Fonseca EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr 2017; 171: 288–295.
[11] Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019- nCoV pneumonia. Transl Pediatr 2020; 9: 51–60.
[12] Mehta P, Zimba O, Gasparyan AY, Seiil B, Yessirkepov M. Ethics committees: Structure, roles, and issues. J Korean Med Sci 2023; 38: e198.
[13] Misra DP, Zimba O, Gasparyan AY. Statistical data presentation: A primer for rheumatology researchers. Rheumatol Int 2021; 41: 43–55.
[14] Kumar D, Verma S, Mysorekar IU. COVID-19 and pregnancy: Clinical outcomes; mechanisms, and vaccine efficacy. Transl Res 2022: 251: 84–95.
[15] Clinical protocol for the diagnosis and treatment of coronavirus infection COVID-19 in pregnant women, women in labor and puerperas of August 5, 2021. Available at: http://www.rcrz.kz/index.php/ru/2017-03-12-10-50-44/ press-reliz/2365-press-reliz.16.07.2022.
[16] Kurmanova A, Urazbayeva G, Terlikbayeva A, Salimbaeva D, Ayazbekov A. Diagnostic significance of blood lymphocyte activation markers in pre-eclampsia. Clin Exp Immunol 2024; 215: 94–103.
[17] Ayazbekov A, Nurkhasimova R, Kulbayeva S, Bolat K, Kurmanova AM, Yeskarayeva A, et al. Features of pregnancy, childbirth and postpartum period of young mothers. Electron J Gen Med 2020; 17: em260.
[18] Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and pregnancy: What obstetricians need to know. Am J Obstet Gynecol 2020; 222: 415–426.
[19] Bayakhmetova M, Abuova GN, Bukharbayev YB, Ablyazimov TN, Kamytbekova KZ, Baimbetova S. Q fever in individuals in the Eurasian continent: A 50-year literature review (1973–2022). Arch Clin Infect Dis 2023; 18: e136333.